江西百盈国际药业股份有限公司简介
江西百盈国际药业股份有限公司成立于2004年 ，2023年2月在北交所挂牌上市（证券简称：百盈国际，证券代码 ：873167），公司注册资金7086.125万元 ，是一家集化学原料药、化学药品制剂及中成药的研发、生产与销售为一体的国家高新技术企业 、省级民营企业、省级技术中心企业。公司原料药产品主要为葡萄糖酸钙、葡萄糖酸锌 、葡萄糖酸亚铁等葡萄糖酸盐系列原料药，市场份额位居行业前列；公司主要化学药品制剂为维生素C咀嚼片、复方银翘氨敏胶囊、酚氨咖敏片等，属于维生素类用药和感冒类用药；主要中成药为心脑康胶囊、感冒灵胶囊、儿宝膏，属于心脑血管类用药 、感冒类用药和补益类用药。
自成立以来，公司就高度重视研发工作，始终把“务实创新”作为企业的文化理念。公司已建立一支专业的研发团队，专注于药学研究、新药开发与生产工艺的改进提升 。截至2023年12月31日 ，公司拥有技术人员共22人 ，占2023年末公司总人数的5.61% 。目前公司共有在研项目14个，涵盖消化道类、心脑血管类、感冒类、维生素类等多个领域 ，专注于仿制药的研发与生产工艺的改进。公司积极与外部CRO建立合作关系，充分借助科研机构技术力量开展研发合作，实现优势互补。
自成立以来，公司就高度重视研发工作，始终把“务实创新”作为企业的文化理念。公司已建立一支专业的研发团队，专注于药学研究、新药开发与生产工艺的改进提升 。截至2023年12月31日 ，公司拥有技术人员共22人 ，占2023年末公司总人数的5.61% 。目前公司共有在研项目14个，涵盖消化道类、心脑血管类、感冒类、维生素类等多个领域 ，专注于仿制药的研发与生产工艺的改进。公司积极与外部CRO建立合作关系，充分借助科研机构技术力量开展研发合作，实现优势互补。
Introduction to Jiangxi XinGanJiang Pharmaceutical Co., Ltd.
Jiangxi XinGanJiang Pharmaceutical Co., Ltd. was established in 2004 and was listed on the Beijing Stock Exchange in February 2023 (stock abbreviation: XinGanJiang, stock code: 873167). The company has a registered capital of 70.86125 million yuan and is recognized as a national high-tech enterprise, a provincial-level private enterprise, and a provincial-level technology center enterprise.
The company specializes in the research, development, production, and sales of Active Pharmaceutical Ingredient, chemical drug formulations, and traditional Chinese medicine. Its main raw material products include calcium gluconate, zinc gluconate, and ferrous gluconate, which are part of the gluconate series and hold a leading market share in the industry. The primary chemical drug formulations include vitamin C chewable tablets, compound Yinqiao antihistamine capsules, and phenylephrine and acetaminophen tablets, which fall under the categories of vitamin medications and cold remedies. The main traditional Chinese medicines include Xinnaokang capsules, Ganmaoling capsules, and Erbao ointment, which are classified as cardiovascular medications, cold remedies, and tonics.
Since its inception, the company has placed a strong emphasis on research and development, consistently adhering to the cultural philosophy of "pragmatic innovation." A professional R&D team has been established, focusing on pharmaceutical research, new drug development, and the improvement of production processes. As of December 31, 2023, the company employs 22 technical personnel, accounting for 5.61% of the total workforce. Currently, there are 14 ongoing research projects covering various fields, including gastrointestinal, cardiovascular, cold remedies, and vitamins, with a focus on the development and process improvement of generic drugs. The company actively collaborates with external Contract Research Organizations (CROs) to leverage the technical capabilities of research institutions, achieving complementary advantages in research and development.
The company specializes in the research, development, production, and sales of Active Pharmaceutical Ingredient, chemical drug formulations, and traditional Chinese medicine. Its main raw material products include calcium gluconate, zinc gluconate, and ferrous gluconate, which are part of the gluconate series and hold a leading market share in the industry. The primary chemical drug formulations include vitamin C chewable tablets, compound Yinqiao antihistamine capsules, and phenylephrine and acetaminophen tablets, which fall under the categories of vitamin medications and cold remedies. The main traditional Chinese medicines include Xinnaokang capsules, Ganmaoling capsules, and Erbao ointment, which are classified as cardiovascular medications, cold remedies, and tonics.
Since its inception, the company has placed a strong emphasis on research and development, consistently adhering to the cultural philosophy of "pragmatic innovation." A professional R&D team has been established, focusing on pharmaceutical research, new drug development, and the improvement of production processes. As of December 31, 2023, the company employs 22 technical personnel, accounting for 5.61% of the total workforce. Currently, there are 14 ongoing research projects covering various fields, including gastrointestinal, cardiovascular, cold remedies, and vitamins, with a focus on the development and process improvement of generic drugs. The company actively collaborates with external Contract Research Organizations (CROs) to leverage the technical capabilities of research institutions, achieving complementary advantages in research and development.
